Published in Transplantation on February 15, 2006
Science of composite tissue allotransplantation. Transplantation (2008) 1.05
Evidence that FoxP3+ regulatory T cells may play a role in promoting long-term acceptance of composite tissue allotransplants. Transplantation (2011) 0.96
Vascularized composite tissue allotransplantation--state of the art. Clin Transplant (2013) 0.90
Review of the early diagnoses and assessment of rejection in vascularized composite allotransplantation. Clin Dev Immunol (2013) 0.83
The need for inducing tolerance in vascularized composite allotransplantation. Clin Dev Immunol (2012) 0.79
Site-specific immunosuppression in vascularized composite allotransplantation: prospects and potential. Clin Dev Immunol (2013) 0.79
Experimental Forelimb Allotransplantation in Canine Model. Biomed Res Int (2016) 0.78
Role of donor-specific regulatory T cells in long-term acceptance of rat hind limb allograft. PLoS One (2012) 0.76
In vivo observations of cell trafficking in allotransplanted vascularized skin flaps and conventional skin grafts. J Plast Reconstr Aesthet Surg (2009) 0.76
Split rejection in vascularized composite allotransplantation. Eplasty (2013) 0.76
Current status of vascularized composite tissue allotransplantation. Burns Trauma (2014) 0.75
Dynamic expression of Qa-2 during acute graft rejection. Mol Med (2010) 0.75
Systematic analysis of composite tissue allograft rejection. Transplantation (2006) 0.75
Mycophenolic acid derivative 118 improves outcome of skin grafts by suppressing IL-17 production. Acta Pharmacol Sin (2013) 0.75
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med (2010) 13.33
Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med (2011) 6.35
Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology (2006) 4.90
Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med (2014) 4.70
Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci U S A (2006) 4.10
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology (2004) 3.61
Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest (2010) 3.59
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology (2010) 3.55
Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology (2011) 3.46
Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA (2011) 3.37
Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology (2010) 2.86
Gastrointestinal involvement in chronic granulomatous disease. Pediatrics (2004) 2.80
Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology (2009) 2.78
Progression of fibrosis in chronic hepatitis C. Gastroenterology (2003) 2.77
The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology (2010) 2.75
Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant (2005) 2.70
Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biol Blood Marrow Transplant (2006) 2.63
Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation (2003) 2.48
Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology (2011) 2.44
The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology (2011) 2.42
Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology (2011) 2.39
Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation, despite immunosuppression, is associated with autoantibodies and pathogenic autoreactive CD4 T-cells. Diabetes (2010) 2.36
Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology (2011) 2.25
When and why portal vein thrombosis matters in liver transplantation: a critical audit of 174 cases. Ann Surg (2014) 2.23
Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials (2008) 2.17
Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatology (2013) 2.17
Composite tissue allotransplantation: development of a preclinical model in nonhuman primates. Transplantation (2005) 2.08
Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol (2003) 2.05
Diagnostic testing of vitrectomy specimens. Am J Ophthalmol (2005) 2.03
Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology (2010) 1.98
A role for angiotensin II type 1 receptors on bone marrow-derived cells in the pathogenesis of angiotensin II-dependent hypertension. Hypertension (2009) 1.94
The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology (2007) 1.92
Donor-specific B-cell tolerance after ABO-incompatible infant heart transplantation. Nat Med (2004) 1.92
Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain (2009) 1.91
Cellular and tissue localization of globotriaosylceramide in Fabry disease. Virchows Arch (2007) 1.91
Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. Hepatology (2003) 1.87
A novel role for type 1 angiotensin receptors on T lymphocytes to limit target organ damage in hypertension. Circ Res (2012) 1.79
Peripheral CD4(+)CD8(+) T cells are differentiated effector memory cells with antiviral functions. Blood (2004) 1.77
Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy. Lancet (2002) 1.76
Modeling pathogenesis of primary liver cancer in lineage-specific mouse cell types. Gastroenterology (2013) 1.76
Lymphocyte responses exacerbate angiotensin II-dependent hypertension. Am J Physiol Regul Integr Comp Physiol (2010) 1.76
Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates. Nat Med (2009) 1.76
The liver diseases of lipodystrophy: the long-term effect of leptin treatment. J Hepatol (2013) 1.72
Stimulation of lymphocyte responses by angiotensin II promotes kidney injury in hypertension. Am J Physiol Renal Physiol (2008) 1.71
Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology (2010) 1.70
APOL1 Genotype and Kidney Transplantation Outcomes From Deceased African American Donors. Transplantation (2016) 1.68
Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992-2008. Hepatology (2012) 1.68
Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease. J Hepatol (2008) 1.67
A novel bacterium associated with lymphadenitis in a patient with chronic granulomatous disease. PLoS Pathog (2006) 1.66
Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology (2005) 1.63
Causes of death in hyper-IgE syndrome. J Allergy Clin Immunol (2007) 1.61
The impact of renal function on outcomes of bariatric surgery. J Am Soc Nephrol (2012) 1.60
Heterotopic uterus transplantation in a swine model. Transplantation (2009) 1.59
A spectrum of severe familial liver disorders associate with telomerase mutations. PLoS One (2009) 1.57
Transplantation of the abdominal wall. Lancet (2003) 1.51
Small molecule-mediated activation of the integrin CD11b/CD18 reduces inflammatory disease. Sci Signal (2011) 1.51
CD2AP in mouse and human podocytes controls a proteolytic program that regulates cytoskeletal structure and cellular survival. J Clin Invest (2011) 1.49
Ethnicity greatly influences cytokine gene polymorphism distribution. Am J Transplant (2002) 1.48
Mechanisms of the proteinuria induced by Rho GTPases. Kidney Int (2012) 1.48
Nodular regenerative hyperplasia: not all nodules are created equal. Hepatology (2006) 1.44
Segmental xanthomatosis of the small intestine. A case report and review of the literature. Hum Pathol (2008) 1.43
Factors that identify survival after liver retransplantation for allograft failure caused by recurrent hepatitis C infection. Liver Transpl (2004) 1.42
LFA-1-specific therapy prolongs allograft survival in rhesus macaques. J Clin Invest (2010) 1.41
Glomerular type 1 angiotensin receptors augment kidney injury and inflammation in murine autoimmune nephritis. J Clin Invest (2009) 1.41
Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid. J Immunol (2004) 1.40
Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with deoxyspergualin. Transplantation (2005) 1.40
Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology (2007) 1.40
Intragraft transcriptome level of CXCL9 as biomarker of acute cellular rejection after liver transplantation. J Surg Res (2012) 1.39
Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood (2011) 1.39
Cyclical Cushing syndrome presenting in infancy: an early form of primary pigmented nodular adrenocortical disease, or a new entity? J Clin Endocrinol Metab (2004) 1.38
Cutting edge: Rapamycin augments pathogen-specific but not graft-reactive CD8+ T cell responses. J Immunol (2010) 1.38
Ocular adnexal lymphoma: a clinicopathologic study of a large cohort of patients with no evidence for an association with Chlamydia psittaci. Blood (2005) 1.38
100 multivisceral transplants at a single center. Ann Surg (2005) 1.34
Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterology (2003) 1.34
Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. Hum Pathol (2004) 1.32
A retrospective review of liver transplant patients treated with sirolimus from a single center: an analysis of sirolimus-related complications. Transplantation (2004) 1.30
Host-dependent patterns of tissue injury in invasive pulmonary aspergillosis. Am J Clin Pathol (2007) 1.29
Alemtuzumab (Campath-1H) combined with tacrolimus in intestinal and multivisceral transplantation. Transplantation (2003) 1.28
Cancers as wounds that do not heal: differences and similarities between renal regeneration/repair and renal cell carcinoma. Cancer Res (2006) 1.26
Intestinal and multivisceral transplantation. World J Surg (2001) 1.25
Functionally significant renal allograft rejection is defined by transcriptional criteria. Am J Transplant (2005) 1.25
Decreased expression of the Ets family transcription factor Fli-1 markedly prolongs survival and significantly reduces renal disease in MRL/lpr mice. J Immunol (2004) 1.24
Intestinal and multivisceral transplantation in children. Ann Surg (2006) 1.22
Hepatic abscess in patients with chronic granulomatous disease. Ann Surg (2002) 1.22
Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepatology (2014) 1.19
Fibrosis progression in African Americans and Caucasian Americans with chronic hepatitis C. Clin Gastroenterol Hepatol (2008) 1.19
Effect of donor factors on early graft survival in adult cadaveric renal transplantation. Am J Transplant (2002) 1.19
Liver biopsy findings in chronic hepatitis B. Hepatology (2009) 1.18
Podocyte-specific overexpression of wild type or mutant trpc6 in mice is sufficient to cause glomerular disease. PLoS One (2010) 1.18
Impact of a selenium chemoprevention clinical trial on hospital admissions of HIV-infected participants. HIV Clin Trials (2002) 1.14
Molecular and immunohistochemical characterization of the onset and resolution of human renal allograft ischemia-reperfusion injury. Transplantation (2002) 1.14
Antitumor effects in mice of the intravenous injection of attenuated Salmonella typhimurium. J Immunother (2002) 1.14
IDEC-131 (anti-CD154), sirolimus and donor-specific transfusion facilitate operational tolerance in non-human primates. Am J Transplant (2005) 1.13
Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology (2010) 1.12
Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN prospective study. J Pediatr Gastroenterol Nutr (2011) 1.12